Despite recent progress in women’s health issues, there are still many challenges women continue to face when accessing healthcare. Here, Alison Slingsby of HRA Pharma discusses the recent advancements made in the UK and where further development is required.
List view / Grid view
The safety and efficacy of fezolinetant is being evaluated in the Phase III trial of over 1,800 women seeking relief from severe vasomotor symptoms associated with menopause (VMS).
Bayer will acquire KaNDy Therapeutics Ltd for an upfront cost of $425 million to expand its drug development pipeline in women’s healthcare.
The EMA has suggested that the safety information be updated for HRT, to reflect a higher risk of breast cancer and recommends new measures for the handling of leuprorelin depot medicines.
Around half of HRT products have been reported as out of stock in UK pharmacies due to supply issues in China, leading to a shortage.
Women who undergo hormone therapy to relieve menopausal symptoms tend to have less fat tissue, particularly in the abdomen, than other menopausal women...
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days...